{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:45:09Z","timestamp":1794271509240,"version":"4.9.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New drugs may in some cases need to be tested in paediatric and pregnant patients. However, it is difficult to recruit such patients and there are many ethical issues around their inclusion in clinical trials. Modelling and simulation can help to plan well-designed clinical trials with a reduced number of participants and to bridge gaps where recruitment is difficult. Physiologically based pharmacokinetic (PBPK) models for small molecule drugs have been used to aid study design and dose adjustments in paediatrics and pregnancy, with several publications in the literature. However, published PBPK models for monoclonal antibodies (mAb) in these populations are scarce. Here, the current status of mAb PBPK models in paediatrics and pregnancy is discussed. Seven mAb PBPK models published for paediatrics were found, which report good prediction accuracy across a wide age range. No mAb PBPK models for pregnant women have been published to date. Current challenges to the development of such PBPK models are discussed, including gaps in our knowledge of relevant physiological processes and availability of clinical data to verify models. As the availability of such data increases, it will help to improve our confidence in the PBPK model predictive ability. Advantages for using PBPK models to predict mAb PK in paediatrics and pregnancy are discussed. For example, the ability to incorporate ontogeny and gestational changes in physiology, prediction of maternal, placental and foetal exposure and the ability to make predictions from<jats:italic>in vitro<\/jats:italic>and preclinical data prior to clinical data being available.<\/jats:p>","DOI":"10.1208\/s12248-022-00722-0","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T22:19:31Z","timestamp":1654121971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy"],"prefix":"10.1208","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-5173","authenticated-orcid":false,"given":"Katherine L.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"8","key":"722_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/jcph.1406","volume":"59","author":"XI Liu","year":"2019","unstructured":"Liu XI, Dallmann A, Wang YM, Green DJ, Burnham JM, Chiang B, et al. Monoclonal antibodies and Fc-fusion proteins for pediatric use: dosing, immunogenicity, and modeling and simulation in data submitted to the US Food and Drug Administration. J Clin Pharmacol. 2019;59(8):1130\u201343. https:\/\/doi.org\/10.1002\/jcph.1406.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"722_CR2","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1002\/jcph.1829","volume":"61","author":"PRV Malik","year":"2021","unstructured":"Malik PRV, Temrikar ZH, Chelle P, Edginton AN, Meibohm B. Pediatric dose selection for therapeutic proteins. J Clin Pharmacol. 2021;61(Suppl 1):S193-s206. https:\/\/doi.org\/10.1002\/jcph.1829.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"722_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bcp.14145","volume":"86","author":"N Ghalandari","year":"2020","unstructured":"Ghalandari N, Dolhain R, Hazes JMW, Siezen CLE, van der Laan JW, Crijns H, et al. The pre- and post-authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation. Br J Clin Pharmacol. 2020;86(3):580\u201390. https:\/\/doi.org\/10.1111\/bcp.14145.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"722_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","volume":"53","author":"KL Hyrich","year":"2014","unstructured":"Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53(8):1377\u201385. https:\/\/doi.org\/10.1093\/rheumatology\/ket409.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"722_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/all.14282","volume":"76","author":"B Pfaller","year":"2021","unstructured":"Pfaller B, Jos\u00e9 Yepes-Nu\u00f1ez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy. 2021;76(1):71\u201389. https:\/\/doi.org\/10.1111\/all.14282.","journal-title":"Allergy"},{"issue":"4","key":"722_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.20344\/amp.11482","volume":"32","author":"J Roseira","year":"2019","unstructured":"Roseira J, Ramos J. A narrative review on anti-tumor necrosis factor \u03b1 therapies in inflammatory bowel disease during pregnancy: immunoglobulin placental translocation and its impact. Acta Med Port. 2019;32(4):305\u201312. https:\/\/doi.org\/10.20344\/amp.11482.","journal-title":"Acta Med Port"},{"issue":"9\u201310","key":"722_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10354-012-0085-0","volume":"162","author":"I Ellinger","year":"2012","unstructured":"Ellinger I, Fuchs R. HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn. Wien Med Wochenschr. 2012;162(9\u201310):207\u201313. https:\/\/doi.org\/10.1007\/s10354-012-0085-0.","journal-title":"Wien Med Wochenschr"},{"issue":"2","key":"722_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ajog.2021.04.211","volume":"225","author":"JB Bussel","year":"2021","unstructured":"Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2021;225(2):120\u20137. https:\/\/doi.org\/10.1016\/j.ajog.2021.04.211.","journal-title":"Am J Obstet Gynecol"},{"key":"722_CR9","doi-asserted-by":"publisher","unstructured":"Roy S, Nanovskaya T, Patrikeeva S, Cochran E, Parge V, Guess J et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex\u00a0vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498.e1-.e9. https:\/\/doi.org\/10.1016\/j.ajog.2019.02.058.","DOI":"10.1016\/j.ajog.2019.02.058"},{"issue":"10","key":"722_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/apt.14040","volume":"45","author":"CH Seow","year":"2017","unstructured":"Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1329\u201338. https:\/\/doi.org\/10.1111\/apt.14040.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"722_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/apt.16102","volume":"52","author":"E Flanagan","year":"2020","unstructured":"Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(10):1551\u201362. https:\/\/doi.org\/10.1111\/apt.16102.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"722_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1136\/ard.2008.105924","volume":"68","author":"A Murashima","year":"2009","unstructured":"Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant\u2019s serum. Ann Rheum Dis. 2009;68(11):1793\u20134. https:\/\/doi.org\/10.1136\/ard.2008.105924.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"722_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cpt.1827","volume":"108","author":"GAM Eliesen","year":"2020","unstructured":"Eliesen GAM, van Drongelen J, van Hove H, Kooijman NI, van den Broek P, de Vries A, et al. Assessment of placental disposition of infliximab and etanercept in women with autoimmune diseases and in the ex vivo perfused placenta. Clin Pharmacol Ther. 2020;108(1):99\u2013106. https:\/\/doi.org\/10.1002\/cpt.1827.","journal-title":"Clin Pharmacol Ther"},{"key":"722_CR14","doi-asserted-by":"publisher","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286\u201392; quiz e24. https:\/\/doi.org\/10.1016\/j.cgh.2012.11.011.","DOI":"10.1016\/j.cgh.2012.11.011"},{"key":"722_CR15","doi-asserted-by":"publisher","unstructured":"Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T et al. Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. Therap Adv Gastroenterol. 2021;14:17562848211032790. https:\/\/doi.org\/10.1177\/17562848211032790.","DOI":"10.1177\/17562848211032790"},{"issue":"1","key":"722_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","volume":"151","author":"M Julsgaard","year":"2016","unstructured":"Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2016.04.002.","journal-title":"Gastroenterology"},{"issue":"9","key":"722_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","volume":"33","author":"Z Zelinkova","year":"2011","unstructured":"Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33(9):1053\u20138. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04617.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"722_CR18","first-page":"1426","volume":"91","author":"B Friedrichs","year":"2006","unstructured":"Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica. 2006;91(10):1426\u20137.","journal-title":"Haematologica"},{"issue":"7","key":"722_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","volume":"71","author":"A Haghikia","year":"2014","unstructured":"Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891\u20135. https:\/\/doi.org\/10.1001\/jamaneurol.2014.209.","journal-title":"JAMA Neurol"},{"issue":"2","key":"722_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, Flynn AD, Molt\u00f3 A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212196.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"722_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/03009742.2019.1639821","volume":"49","author":"M Moriyama","year":"2020","unstructured":"Moriyama M, Wada Y, Minamoto T, Kondo M, Honda M, Murakawa Y. Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report. Scand J Rheumatol. 2020;49(2):165\u20136. https:\/\/doi.org\/10.1080\/03009742.2019.1639821.","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"722_CR22","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/rheumatology\/kez100","volume":"58","author":"J Saito","year":"2019","unstructured":"Saito J, Yakuwa N, Kaneko K, Takai C, Goto M, Nakajima K, et al. Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum. Rheumatology (Oxford). 2019;58(8):1505\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kez100.","journal-title":"Rheumatology (Oxford)"},{"key":"722_CR23","doi-asserted-by":"publisher","unstructured":"Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology. J Pharm Sci. 2019;108(1):21\u20135. https:\/\/doi.org\/10.1016\/j.xphs.2018.10.033.","DOI":"10.1016\/j.xphs.2018.10.033"},{"issue":"2","key":"722_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4155\/ipk-2016-0025","volume":"2","author":"S Cole","year":"2017","unstructured":"Cole S, Hay JL, Luzon E, Nordmark A, Rusten IS. European regulatory perspective on pediatric physiologically based pharmacokinetic models. Int J Pharmacokinet. 2017;2(2):113\u201324. https:\/\/doi.org\/10.4155\/ipk-2016-0025.","journal-title":"Int J Pharmacokinet"},{"issue":"8","key":"722_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013;2(8): e63. https:\/\/doi.org\/10.1038\/psp.2013.41.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"722_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1208\/s12248-018-0187-8","volume":"20","author":"IE Templeton","year":"2018","unstructured":"Templeton IE, Jones NS, Musib L. Pediatric dose selection and utility of PBPK in determining dose. AAPS J. 2018;20(2):31. https:\/\/doi.org\/10.1208\/s12248-018-0187-8.","journal-title":"AAPS J"},{"issue":"1","key":"722_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-018-0677-y","volume":"58","author":"V Yellepeddi","year":"2019","unstructured":"Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CMT. State-of-the-art review on physiologically based pharmacokinetic modeling in pediatric drug development. Clin Pharmacokinet. 2019;58(1):1\u201313. https:\/\/doi.org\/10.1007\/s40262-018-0677-y.","journal-title":"Clin Pharmacokinet"},{"key":"722_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.733823","volume":"9","author":"N Chaphekar","year":"2021","unstructured":"Chaphekar N, Dodeja P, Shaik IH, Caritis S, Venkataramanan R. Maternal-fetal pharmacology of drugs: a review of current status of the application of physiologically based pharmacokinetic models. Front Pediatr. 2021;9: 733823. https:\/\/doi.org\/10.3389\/fped.2021.733823.","journal-title":"Front Pediatr"},{"issue":"6","key":"722_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","volume":"39","author":"Y Cao","year":"2012","unstructured":"Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39(6):711\u201323. https:\/\/doi.org\/10.1007\/s10928-012-9280-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"722_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","volume":"52","author":"M Dostalek","year":"2013","unstructured":"Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83\u2013124. https:\/\/doi.org\/10.1007\/s40262-012-0027-4.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"722_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67\u201386. https:\/\/doi.org\/10.1007\/s10928-011-9232-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"722_CR32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1208\/s12248-014-9640-5","volume":"16","author":"L Li","year":"2014","unstructured":"Li L, Gardner I, Dostalek M, Jamei M. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J. 2014;16(5):1097\u2013109. https:\/\/doi.org\/10.1208\/s12248-014-9640-5.","journal-title":"AAPS J"},{"issue":"1","key":"722_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.dmpk.2018.11.002","volume":"34","author":"PM Glassman","year":"2019","unstructured":"Glassman PM, Balthasar JP. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metab Pharmacokinet. 2019;34(1):3\u201313. https:\/\/doi.org\/10.1016\/j.dmpk.2018.11.002.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"722_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","volume":"34","author":"A Garg","year":"2007","unstructured":"Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687\u2013709. https:\/\/doi.org\/10.1007\/s10928-007-9065-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"722_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/2040-2384-2-14","volume":"2","author":"H Sarin","year":"2010","unstructured":"Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010;2:14. https:\/\/doi.org\/10.1186\/2040-2384-2-14.","journal-title":"J Angiogenes Res"},{"key":"722_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev.immunol.18.1.739","volume":"18","author":"V Ghetie","year":"2000","unstructured":"Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol. 2000;18:739\u201366. https:\/\/doi.org\/10.1146\/annurev.immunol.18.1.739.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"722_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248\u201352. https:\/\/doi.org\/10.1038\/clpt.1994.134.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"722_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012;14(2):296\u2013302. https:\/\/doi.org\/10.1208\/s12248-012-9340-y.","journal-title":"AAPS J"},{"issue":"1","key":"722_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34\u201347. https:\/\/doi.org\/10.1038\/nri2206.","journal-title":"Nat Rev Immunol"},{"issue":"1 Suppl","key":"722_CR40","doi-asserted-by":"publisher","first-page":"54s","DOI":"10.1177\/0091270011413894","volume":"52","author":"B Meibohm","year":"2012","unstructured":"Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52(1 Suppl):54s\u201362s. https:\/\/doi.org\/10.1177\/0091270011413894.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"722_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","volume":"51","author":"K Abduljalil","year":"2012","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365\u201396. https:\/\/doi.org\/10.2165\/11597440-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"722_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-017-0618-1","volume":"57","author":"K Abduljalil","year":"2018","unstructured":"Abduljalil K, Johnson TN, Rostami-Hodjegan A. Fetal physiologically-based pharmacokinetic models: systems information on fetal biometry and gross composition. Clin Pharmacokinet. 2018;57(9):1149\u201371. https:\/\/doi.org\/10.1007\/s40262-017-0618-1.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"722_CR43","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s40262-017-0538-0","volume":"56","author":"A Dallmann","year":"2017","unstructured":"Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women. Clin Pharmacokinet. 2017;56(12):1525\u201341. https:\/\/doi.org\/10.1007\/s40262-017-0538-0.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"722_CR44","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1208\/s12248-013-9505-3","volume":"15","author":"B Xia","year":"2013","unstructured":"Xia B, Heimbach T, Gollen R, Nanavati C, He H. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J. 2013;15(4):1012\u201324. https:\/\/doi.org\/10.1208\/s12248-013-9505-3.","journal-title":"AAPS J"},{"issue":"10","key":"722_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013\u201334. https:\/\/doi.org\/10.2165\/00003088-200645100-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"722_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14(6):585\u201399. https:\/\/doi.org\/10.1080\/17425255.2018.1482278.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"722_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","volume":"22","author":"ZH Temrikar","year":"2020","unstructured":"Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs. 2020;22(2):199\u2013216. https:\/\/doi.org\/10.1007\/s40272-020-00382-7.","journal-title":"Paediatr Drugs"},{"key":"722_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1542\/peds.28.2.169","volume":"28","author":"B Friis-Hansen","year":"1961","unstructured":"Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961;28:169\u201381.","journal-title":"Pediatrics"},{"issue":"1","key":"722_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ar.1091930102","volume":"193","author":"DA Hay","year":"1979","unstructured":"Hay DA, Evan AP. Maturation of the glomerular visceral epithelium and capillary endothelium in the puppy kidney. Anat Rec. 1979;193(1):1\u201321. https:\/\/doi.org\/10.1002\/ar.1091930102.","journal-title":"Anat Rec"},{"issue":"2","key":"722_CR50","first-page":"50","volume":"29","author":"SA Johnson","year":"1996","unstructured":"Johnson SA, Vander Straten MC, Parellada JA, Schnakenberg W, Gest AL. Thoracic duct function in fetal, newborn, and adult sheep. Lymphology. 1996;29(2):50\u20136.","journal-title":"Lymphology"},{"issue":"2","key":"722_CR51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1152\/ajplegacy.1967.213.2.441","volume":"213","author":"PM Taylor","year":"1967","unstructured":"Taylor PM, Boonyaprakob U, Waterman V, Watson D, Lopata E. Clearances of plasma proteins from pulmonary vascular beds of adult dogs and pups. Am J Physiol. 1967;213(2):441\u20139. https:\/\/doi.org\/10.1152\/ajplegacy.1967.213.2.441.","journal-title":"Am J Physiol"},{"issue":"9","key":"722_CR52","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1128\/aac.06446-11","volume":"56","author":"GJ Robbie","year":"2012","unstructured":"Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56(9):4927\u201336. https:\/\/doi.org\/10.1128\/aac.06446-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"722_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000385919","volume":"13","author":"TA Waldmann","year":"1969","unstructured":"Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog. Allergy. 1969;13:1\u2013110. https:\/\/doi.org\/10.1159\/000385919.","journal-title":"Allergy"},{"issue":"2","key":"722_CR54","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s0022-3476(68)80324-5","volume":"72","author":"M Allansmith","year":"1968","unstructured":"Allansmith M, McClellan BH, Butterworth M, Maloney JR. The development of immunoglobulin levels in man. J Pediatr. 1968;72(2):276\u201390. https:\/\/doi.org\/10.1016\/s0022-3476(68)80324-5.","journal-title":"J Pediatr"},{"issue":"4","key":"722_CR55","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1208\/s12248-020-00460-1","volume":"22","author":"X Pan","year":"2020","unstructured":"Pan X, Stader F, Abduljalil K, Gill KL, Johnson TN, Gardner I, et al. Development and application of a physiologically-based pharmacokinetic model to predict the pharmacokinetics of therapeutic proteins from full-term neonates to adolescents. AAPS J. 2020;22(4):76. https:\/\/doi.org\/10.1208\/s12248-020-00460-1.","journal-title":"AAPS J"},{"issue":"2","key":"722_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/10799893.2013.865745","volume":"34","author":"Z Tian","year":"2014","unstructured":"Tian Z, Sutton BJ, Zhang X. Distribution of rat neonatal Fc receptor in the principal organs of neonatal and pubertal rats. J Recept Signal Transduct Res. 2014;34(2):137\u201342. https:\/\/doi.org\/10.3109\/10799893.2013.865745.","journal-title":"J Recept Signal Transduct Res"},{"key":"722_CR57","unstructured":"Limothai W, Meibohm B, editors. Effect of developmental growth and FcRn expresion on the pharmacokinetics of monocolnal antibodies in mice. World Conference on Pharmacometrics; 2016; Brisbane."},{"issue":"5","key":"722_CR58","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","volume":"36","author":"A Malek","year":"1996","unstructured":"Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248\u201355. https:\/\/doi.org\/10.1111\/j.1600-0897.1996.tb00172.x.","journal-title":"Am J Reprod Immunol"},{"issue":"2","key":"722_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/bf00919271","volume":"13","author":"H Sarvas","year":"1993","unstructured":"Sarvas H, Sepp\u00e4l\u00e4 I, Kurikka S, Siegberg R, M\u00e4kel\u00e4 O. Half-life of the maternal IgG1 allotype in infants. J Clin Immunol. 1993;13(2):145\u201351. https:\/\/doi.org\/10.1007\/bf00919271.","journal-title":"J Clin Immunol"},{"issue":"1","key":"722_CR60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1600-0897.1998.tb00329.x","volume":"39","author":"M Palfi","year":"1998","unstructured":"Palfi M, Selbing A. Placental transport of maternal immunoglobulin G. Am J Reprod Immunol. 1998;39(1):24\u20136. https:\/\/doi.org\/10.1111\/j.1600-0897.1998.tb00329.x.","journal-title":"Am J Reprod Immunol"},{"issue":"4","key":"722_CR61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1600-0897.1994.tb00866.x","volume":"31","author":"KT Ailus","year":"1994","unstructured":"Ailus KT. A follow-up study of immunoglobulin levels and autoantibodies in an unselected pregnant population. Am J Reprod Immunol. 1994;31(4):189\u201396. https:\/\/doi.org\/10.1111\/j.1600-0897.1994.tb00866.x.","journal-title":"Am J Reprod Immunol"},{"issue":"1\u20132","key":"722_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(sici)1097-0029(19970701\/15)38:1\/2<137::Aid-jemt14>3.0.Co;2-q","volume":"38","author":"L Leach","year":"1997","unstructured":"Leach L, Firth JA. Structure and permeability of human placental microvasculature. Microsc Res Tech. 1997;38(1\u20132):137\u201344. https:\/\/doi.org\/10.1002\/(sici)1097-0029(19970701\/15)38:1\/2%3c137::Aid-jemt14%3e3.0.Co;2-q.","journal-title":"Microsc Res Tech"},{"issue":"23","key":"722_CR63","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1042\/cs20171252","volume":"131","author":"V Pang","year":"2017","unstructured":"Pang V, Bates DO, Leach L. Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A(165)a, VEGF-A(165)b. PIGF and VE-cadherin Clin Sci (Lond). 2017;131(23):2763\u201375. https:\/\/doi.org\/10.1042\/cs20171252.","journal-title":"PIGF and VE-cadherin Clin Sci (Lond)"},{"issue":"2","key":"722_CR64","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000236622","volume":"103","author":"OM Avrech","year":"1994","unstructured":"Avrech OM, Samra Z, Lazarovich Z, Caspi E, Jacobovich A, Sompolinsky D. Efficacy of the placental barrier for immunoglobulins: correlations between maternal, paternal and fetal immunoglobulin levels. Int Arch Allergy Immunol. 1994;103(2):160\u20135. https:\/\/doi.org\/10.1159\/000236622.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"722_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0143-4004(80)80018-x","volume":"1","author":"CD Ockleford","year":"1980","unstructured":"Ockleford CD, Clint JM. The uptake of IgG by human placental chorionic villi: a correlated autoradiographic and wide aperture counting study. Placenta. 1980;1(2):91\u2013111. https:\/\/doi.org\/10.1016\/s0143-4004(80)80018-x.","journal-title":"Placenta"},{"key":"722_CR66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","volume":"116","author":"C Porter","year":"2016","unstructured":"Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7\u201312. https:\/\/doi.org\/10.1016\/j.jri.2016.04.284.","journal-title":"J Reprod Immunol"},{"issue":"7","key":"722_CR67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/s0143-4004(03)00101-2","volume":"24","author":"RK Miller","year":"2003","unstructured":"Miller RK, Mace K, Polliotti B, DeRita R, Hall W, Treacy G. Marginal transfer of ReoPro (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. Placenta. 2003;24(7):727\u201338. https:\/\/doi.org\/10.1016\/s0143-4004(03)00101-2.","journal-title":"Placenta"},{"issue":"4","key":"722_CR68","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/bdrb.20201","volume":"86","author":"N Pentsuk","year":"2009","unstructured":"Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328\u201344. https:\/\/doi.org\/10.1002\/bdrb.20201.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"5","key":"722_CR69","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3892\/ijmm.2015.2141","volume":"35","author":"T Ishikawa","year":"2015","unstructured":"Ishikawa T, Takizawa T, Iwaki J, Mishima T, Ui-Tei K, Takeshita T, et al. Fc gamma receptor IIb participates in maternal IgG trafficking of human placental endothelial cells. Int J Mol Med. 2015;35(5):1273\u201389. https:\/\/doi.org\/10.3892\/ijmm.2015.2141.","journal-title":"Int J Mol Med"},{"issue":"6","key":"722_CR70","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1369\/0022155417705095","volume":"65","author":"S Latvala","year":"2017","unstructured":"Latvala S, Jacobsen B, Otteneder MB, Herrmann A, Kronenberg S. Distribution of FcRn across species and tissues. J Histochem Cytochem. 2017;65(6):321\u201333. https:\/\/doi.org\/10.1369\/0022155417705095.","journal-title":"J Histochem Cytochem"},{"issue":"10","key":"722_CR71","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1172\/jci105068","volume":"43","author":"D Gitlin","year":"1964","unstructured":"Gitlin D, Kumate J, Urrusti J, Morales C. The selectivity of the human placenta in the transfer of plasma proteins from mother to fetus. J Clin Invest. 1964;43(10):1938\u201351. https:\/\/doi.org\/10.1172\/jci105068.","journal-title":"J Clin Invest"},{"key":"722_CR72","doi-asserted-by":"publisher","unstructured":"Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol. 2014;4(4). https:\/\/doi.org\/10.4172\/2161-0495.1000209.","DOI":"10.4172\/2161-0495.1000209"},{"issue":"2","key":"722_CR73","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/jpet.110.175083","volume":"336","author":"JJ Hubbard","year":"2011","unstructured":"Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. J Pharmacol Exp Ther. 2011;336(2):414\u201322. https:\/\/doi.org\/10.1124\/jpet.110.175083.","journal-title":"J Pharmacol Exp Ther"},{"key":"722_CR74","unstructured":"Ishii S, Arizono H, Nagao T, Kudo S, Kondo S, Kiyoki M. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Second communication: distribution and elimination of the new monoclonal antibody, regavirumab after repeated administration in rats, and placental transfer and milk-passage study after single administration to pregnant and lactating rats. Arzneimittelforschung. 1994;44(7):899-908."},{"issue":"7","key":"722_CR75","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/eji.1830260718","volume":"26","author":"NE Simister","year":"1996","unstructured":"Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26(7):1527\u201331. https:\/\/doi.org\/10.1002\/eji.1830260718.","journal-title":"Eur J Immunol"},{"issue":"8","key":"722_CR76","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.4049\/jimmunol.157.8.3317","volume":"157","author":"JL Leach","year":"1996","unstructured":"Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol. 1996;157(8):3317\u201322.","journal-title":"J Immunol"},{"issue":"7","key":"722_CR77","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/eji.1830260741","volume":"26","author":"EK Kristoffersen","year":"1996","unstructured":"Kristoffersen EK, Matre R. Co-localization of the neonatal Fc gamma receptor and IgG in human placental term syncytiotrophoblasts. Eur J Immunol. 1996;26(7):1668\u201371. https:\/\/doi.org\/10.1002\/eji.1830260741.","journal-title":"Eur J Immunol"},{"key":"722_CR78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.placenta.2019.02.012","volume":"78","author":"T Kiskova","year":"2019","unstructured":"Kiskova T, Mytsko Y, Schepelmann M, Helmer H, Fuchs R, Miedl H, et al. Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system. Placenta. 2019;78:36\u201343. https:\/\/doi.org\/10.1016\/j.placenta.2019.02.012.","journal-title":"Placenta"},{"issue":"2","key":"722_CR79","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0198-8859(00)00244-5","volume":"62","author":"F Antohe","year":"2001","unstructured":"Antohe F, R\u0103dulescu L, Gafencu A, Ghe\u0163ie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol. 2001;62(2):93\u2013105. https:\/\/doi.org\/10.1016\/s0198-8859(00)00244-5.","journal-title":"Hum Immunol"},{"issue":"2","key":"722_CR80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/aji.12465","volume":"75","author":"Y Wang","year":"2016","unstructured":"Wang Y, Jiang X, He J, Diraviyam T, Zhang X. Quantitative investigation on correlation between IgG and FcRn during gestation and lactating periods in rat. Am J Reprod Immunol. 2016;75(2):81\u20135. https:\/\/doi.org\/10.1111\/aji.12465.","journal-title":"Am J Reprod Immunol"},{"issue":"3","key":"722_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12972","volume":"80","author":"NA Lozano","year":"2018","unstructured":"Lozano NA, Lozano A, Marini V, Saranz RJ, Blumberg RS, Baker K, et al. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. Am J Reprod Immunol. 2018;80(3): e12972. https:\/\/doi.org\/10.1111\/aji.12972.","journal-title":"Am J Reprod Immunol"},{"issue":"6","key":"722_CR82","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1651-2227.1969.tb04765.x","volume":"58","author":"T Berg","year":"1969","unstructured":"Berg T, Nilsson BA. The foetal development of serum levels of IgG and IgM. Acta Paediatr Scand. 1969;58(6):577\u201383. https:\/\/doi.org\/10.1111\/j.1651-2227.1969.tb04765.x.","journal-title":"Acta Paediatr Scand"},{"key":"722_CR83","unstructured":"Mikhael M, Khan YS. Anatomy, abdomen and pelvis, lymphatic drainage. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC.; 2022."},{"issue":"1","key":"722_CR84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/cphy.c180015","volume":"9","author":"JW Breslin","year":"2018","unstructured":"Breslin JW, Yang Y, Scallan JP, Sweat RS, Adderley SP, Murfee WL. Lymphatic vessel network structure and physiology. Compr Physiol. 2018;9(1):207\u201399. https:\/\/doi.org\/10.1002\/cphy.c180015.","journal-title":"Compr Physiol"},{"key":"722_CR85","doi-asserted-by":"publisher","unstructured":"Cataldo Oportus S, de Paiva Rodrigues L, Pereira de Godoy JM, Guerreiro Godoy Mde F. Lymph drainage in pregnant women. Nurs Res Pract. 2013;2013:364582. https:\/\/doi.org\/10.1155\/2013\/364582.","DOI":"10.1155\/2013\/364582"},{"issue":"10","key":"722_CR86","first-page":"1072","volume":"64","author":"FE Hytten","year":"1971","unstructured":"Hytten FE, Robertson EG. Maternal water metabolism in pregnancy. Proc R Soc Med. 1971;64(10):1072.","journal-title":"Proc R Soc Med"},{"issue":"4","key":"722_CR87","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000012837","volume":"44","author":"E Forsum","year":"2000","unstructured":"Forsum E, Forsberg AM, Nilsson E, Bergstr\u00f6m J, Hultman E. Electrolytes, water, RNA, total creatine and calculated resting membrane potential in muscle tissue from pregnant women. Ann Nutr Metab. 2000;44(4):144\u20139. https:\/\/doi.org\/10.1159\/000012837.","journal-title":"Ann Nutr Metab"},{"issue":"2","key":"722_CR88","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jpen.1451","volume":"43","author":"PB Soeters","year":"2019","unstructured":"Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181\u201393. https:\/\/doi.org\/10.1002\/jpen.1451.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"9","key":"722_CR89","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1471-0528.1990.tb02580.x","volume":"97","author":"L Bungum","year":"1990","unstructured":"Bungum L, Tollan A, Oian P. Antepartum to postpartum changes in transcapillary fluid balance. Br J Obstet Gynaecol. 1990;97(9):838\u201342. https:\/\/doi.org\/10.1111\/j.1471-0528.1990.tb02580.x.","journal-title":"Br J Obstet Gynaecol"},{"issue":"6","key":"722_CR90","doi-asserted-by":"publisher","first-page":"H843","DOI":"10.1152\/ajpheart.1981.240.6.H843","volume":"240","author":"RA Brace","year":"1981","unstructured":"Brace RA, Christian JL. Transcapillary Starling pressures in the fetus, newborn, adult, and pregnant adult. Am J Physiol. 1981;240(6):H843\u20137. https:\/\/doi.org\/10.1152\/ajpheart.1981.240.6.H843.","journal-title":"Am J Physiol"},{"issue":"1","key":"722_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/aja.1001420103","volume":"142","author":"RP Bailey","year":"1975","unstructured":"Bailey RP, Weiss L. Ontogeny of human fetal lymph nodes. Am J Anat. 1975;142(1):15\u201327. https:\/\/doi.org\/10.1002\/aja.1001420103.","journal-title":"Am J Anat"},{"issue":"3","key":"722_CR92","first-page":"110","volume":"39","author":"C Bellini","year":"2006","unstructured":"Bellini C, Boccardo F, Bonioli E, Campisi C. Lymphodynamics in the fetus and newborn. Lymphology. 2006;39(3):110\u20137.","journal-title":"Lymphology"},{"key":"722_CR93","doi-asserted-by":"publisher","unstructured":"Eiby YA, Lingwood BE, Wright IMR. Plasma leak from the circulation contributes to poor outcomes for preterm infants: a working hypothesis. Front Neurol. 2021;12:636740-. https:\/\/doi.org\/10.3389\/fneur.2021.636740.","DOI":"10.3389\/fneur.2021.636740"},{"issue":"8","key":"722_CR94","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/00003246-198108000-00002","volume":"9","author":"A Sola","year":"1981","unstructured":"Sola A, Gregory GA. Colloid osmotic pressure of normal newborns and premature infants. Crit Care Med. 1981;9(8):568\u201372. https:\/\/doi.org\/10.1097\/00003246-198108000-00002.","journal-title":"Crit Care Med"},{"issue":"1","key":"722_CR95","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3181\/00379727-131-33809","volume":"131","author":"M Delivoria-Papadopoulos","year":"1969","unstructured":"Delivoria-Papadopoulos M, Battaglia FC, Meschia G. A comparison of fetal versus maternal plasma colloidal osmotic pressure im man. Proc Soc Exp Biol Med. 1969;131(1):84\u20137. https:\/\/doi.org\/10.3181\/00379727-131-33809.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"6","key":"722_CR96","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1542\/peds.68.6.814","volume":"68","author":"PY Wu","year":"1981","unstructured":"Wu PY, Rockwell G, Chan L, Wang SM, Udani V. Colloid osmotic pressure in newborn infants: variations with birth weight, gestational age, total serum solids, and mean arterial pressure. Pediatrics. 1981;68(6):814\u20139.","journal-title":"Pediatrics"},{"key":"722_CR97","doi-asserted-by":"publisher","unstructured":"Baum JD, Eisenberg C, Franklin FA, Jr., Meschia G, Battaglia FC. Studies on colloid osmotic pressure in the fetus and newborn infant. With observations on the effects of membranes of various pore sizes. Biol Neonate. 1971;18(3):311\u201320. https:\/\/doi.org\/10.1159\/000240371.","DOI":"10.1159\/000240371"},{"issue":"3","key":"722_CR98","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/gutjnl-2019-318263","volume":"69","author":"J van der Giessen","year":"2020","unstructured":"van der Giessen J, Binyamin D, Belogolovski A, Frishman S, Tenenbaum-Gavish K, Hadar E, et al. Modulation of cytokine patterns and microbiome during pregnancy in IBD. Gut. 2020;69(3):473\u201386. https:\/\/doi.org\/10.1136\/gutjnl-2019-318263.","journal-title":"Gut"},{"issue":"11","key":"722_CR99","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/rheumatology\/ker302","volume":"50","author":"JM Hazes","year":"2011","unstructured":"Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50(11):1955\u201368. https:\/\/doi.org\/10.1093\/rheumatology\/ker302.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"722_CR100","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0896-8411(91)90173-a","volume":"4","author":"GA Rook","year":"1991","unstructured":"Rook GA, Steele J, Brealey R, Whyte A, Isenberg D, Sumar N, et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun. 1991;4(5):779\u201394. https:\/\/doi.org\/10.1016\/0896-8411(91)90173-a.","journal-title":"J Autoimmun"},{"issue":"2","key":"722_CR101","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.placenta.2008.10.012","volume":"30","author":"S Haider","year":"2009","unstructured":"Haider S, Kn\u00f6fler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2009;30(2):111\u201323. https:\/\/doi.org\/10.1016\/j.placenta.2008.10.012.","journal-title":"Placenta"},{"key":"722_CR102","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fphar.2020.00868","volume":"11","author":"S Basu","year":"2020","unstructured":"Basu S, Lien YTK, Vozmediano V, Schlender JF, Eissing T, Schmidt S, et al. Physiologically based pharmacokinetic modeling of monoclonal antibodies in pediatric populations using PK-Sim. Front Pharmacol. 2020;11:868. https:\/\/doi.org\/10.3389\/fphar.2020.00868.","journal-title":"Front Pharmacol"},{"key":"722_CR103","doi-asserted-by":"publisher","unstructured":"Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T. Translational PBPK modeling of the protein therapeutic and CD95L inhibitor asunercept to develop dose recommendations for its first use in pediatric glioblastoma patients. Pharmaceutics. 2019;11(4). https:\/\/doi.org\/10.3390\/pharmaceutics11040152.","DOI":"10.3390\/pharmaceutics11040152"},{"issue":"7","key":"722_CR104","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/19420862.2018.1494479","volume":"10","author":"D Hardiansyah","year":"2018","unstructured":"Hardiansyah D, Ng CM. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. MAbs. 2018;10(7):1144\u201356. https:\/\/doi.org\/10.1080\/19420862.2018.1494479.","journal-title":"MAbs"},{"key":"722_CR105","doi-asserted-by":"publisher","unstructured":"Malik PRV, Edginton AN. Physiologically-based pharmacokinetic modeling vs. allometric scaling for the prediction of infliximab pharmacokinetics in pediatric patients. CPT Pharmacometrics Syst Pharmacol. 2019;8(11):835\u201344. https:\/\/doi.org\/10.1002\/psp4.12456.","DOI":"10.1002\/psp4.12456"},{"issue":"4","key":"722_CR106","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/jcph.1540","volume":"60","author":"PRV Malik","year":"2020","unstructured":"Malik PRV, Edginton AN. Integration of ontogeny into a physiologically based pharmacokinetic model for monoclonal antibodies in premature infants. J Clin Pharmacol. 2020;60(4):466\u201376. https:\/\/doi.org\/10.1002\/jcph.1540.","journal-title":"J Clin Pharmacol"},{"key":"722_CR107","doi-asserted-by":"publisher","unstructured":"Chang HP, Shakhnovich V, Frymoyer A, Funk RS, Becker ML, Park KT et al. A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. Br J Clin Pharmacol. 2021. https:\/\/doi.org\/10.1111\/bcp.14963.","DOI":"10.1111\/bcp.14963"},{"issue":"10","key":"722_CR108","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/apt.16593","volume":"54","author":"M Julsgaard","year":"2021","unstructured":"Julsgaard M, Baumgart DC, Baunwall SMD, Hansen MM, Grosen A, Bibby BM, et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021;54(10):1320\u20139. https:\/\/doi.org\/10.1111\/apt.16593.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"722_CR109","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1586\/14760584.2016.1115351","volume":"15","author":"J Ling","year":"2016","unstructured":"Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines. 2016;15(2):239\u201356. https:\/\/doi.org\/10.1586\/14760584.2016.1115351.","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"722_CR110","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","volume":"4","author":"K Cheent","year":"2010","unstructured":"Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease. J Crohns Colitis. 2010;4(5):603\u20135. https:\/\/doi.org\/10.1016\/j.crohns.2010.05.001.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"722_CR111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7326\/l17-0629","volume":"169","author":"R Labetoulle","year":"2018","unstructured":"Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med. 2018;169(1):60\u20131. https:\/\/doi.org\/10.7326\/l17-0629.","journal-title":"Ann Intern Med"},{"issue":"11","key":"722_CR112","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","volume":"49","author":"BG Berthelsen","year":"2010","unstructured":"Berthelsen BG, Fjelds\u00f8e-Nielsen H, Nielsen CT, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford). 2010;49(11):2225\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keq185.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"722_CR113","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/jcph.1677","volume":"60","author":"Y Xu","year":"2020","unstructured":"Xu Y, Langevin BA, Zhou H, Xu Z. Model-aided adults-to-children pharmacokinetic extrapolation and empirical body size-based dosing exploration for therapeutic monoclonal antibodies-is allometry a reasonable choice? J Clin Pharmacol. 2020;60(12):1573\u201384. https:\/\/doi.org\/10.1002\/jcph.1677.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"722_CR114","doi-asserted-by":"publisher","first-page":"1964935","DOI":"10.1080\/19420862.2021.1964935","volume":"13","author":"E Germovsek","year":"2021","unstructured":"Germovsek E, Cheng M, Giragossian C. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. MAbs. 2021;13(1):1964935. https:\/\/doi.org\/10.1080\/19420862.2021.1964935.","journal-title":"MAbs"},{"issue":"2","key":"722_CR115","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/17425250802691074","volume":"5","author":"M Jamei","year":"2009","unstructured":"Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211\u201323. https:\/\/doi.org\/10.1517\/17425250802691074.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"722_CR116","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","volume":"55","author":"KL Gill","year":"2016","unstructured":"Gill KL, Machavaram KK, Rose RH, Chetty M. Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet. 2016;55(7):789\u2013805. https:\/\/doi.org\/10.1007\/s40262-015-0361-4.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"722_CR117","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/psp4.12461","volume":"8","author":"HM Jones","year":"2019","unstructured":"Jones HM, Zhang Z, Jasper P, Luo H, Avery LB, King LE, et al. A physiologically-based pharmacokinetic model for the prediction of monoclonal antibody pharmacokinetics from in vitro data. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):738\u201347. https:\/\/doi.org\/10.1002\/psp4.12461.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"722_CR118","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10928-016-9482-0","volume":"43","author":"PM Glassman","year":"2016","unstructured":"Glassman PM, Balthasar JP. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2016;43(4):427\u201346. https:\/\/doi.org\/10.1007\/s10928-016-9482-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"722_CR119","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/psp4.12547","volume":"9","author":"HM Jones","year":"2020","unstructured":"Jones HM, Tolsma J, Zhang Z, Jasper P, Luo H, Weber GL, et al. A physiologically-based pharmacokinetic model for the prediction of \u201chalf-life extension\u201d and \u201ccatch and release\u201d monoclonal antibody pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2020;9(9):534\u201341. https:\/\/doi.org\/10.1002\/psp4.12547.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"722_CR120","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/19420862.2017.1417718","volume":"10","author":"LB Avery","year":"2018","unstructured":"Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244\u201355. https:\/\/doi.org\/10.1080\/19420862.2017.1417718.","journal-title":"MAbs"},{"issue":"5","key":"722_CR121","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1080\/19420862.2019.1605270","volume":"11","author":"S Chung","year":"2019","unstructured":"Chung S, Nguyen V, Lin YL, Lafrance-Vanasse J, Scales SJ, Lin K, et al. An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. MAbs. 2019;11(5):942\u201355. https:\/\/doi.org\/10.1080\/19420862.2019.1605270.","journal-title":"MAbs"},{"issue":"1","key":"722_CR122","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/clpt.2011.66","volume":"90","author":"JR Hutson","year":"2011","unstructured":"Hutson JR, Garcia-Bournissen F, Davis A, Koren G. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther. 2011;90(1):67\u201376. https:\/\/doi.org\/10.1038\/clpt.2011.66.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"722_CR123","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.crohns.2011.10.002","volume":"6","author":"C Steenholdt","year":"2012","unstructured":"Steenholdt C, Al-Khalaf M, Ainsworth MA, Brynskov J. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis. 2012;6(3):358\u201361. https:\/\/doi.org\/10.1016\/j.crohns.2011.10.002.","journal-title":"J Crohns Colitis"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-022-00722-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:09:22Z","timestamp":1675728562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-022-00722-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1208\/s12248-022-00722-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katherine L Gill and Hannah M Jones are employees of Certara UK Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"72"}}